Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. This study determined the efficacy, safety and pharmacokinetics of a blonanserin transdermal patch in patients with acutely exacerbated schizophrenia. Methods: This double-blind, multicenter, phase 3 study consisted of a 1-week observation period during which patients were treated with two patches of placebo, followed by a 6-week double-blind period where patients were randomized (1:1:1) to receive once-daily blonanserin 40 mg, blonanserin 80 mg, or placebo patches. The primary endpoint was the change from baseline in the total Positive and Negative Symptom Scale (PANSS) score. Safety assessments included treatment-emergent adverse events (TEAEs). Results: Between December 2014 and October 2018, patients were recruited and randomly assigned to blonanserin 40 mg (n = 196), blonanserin 80 mg (n = 194), or placebo (n = 190); of these, 77.2% completed the study. Compared with placebo, blonanserin significantly improved PANSS total scores at 6 weeks (least square mean [LSM] difference vs placebo: −5.6 with blonanserin 40 mg; 95% confidence interval [CI] −9.6, −1.6; adjusted p = 0.007, and − 10.4 with blonanserin 80 mg; 95% CI −14.4, −6.4; adjusted p b 0.001). Blonanserin was well tolerated; the most common TEAEs reported were application-site erythema and pruritus, akathisia, tremor, and insomnia. Conclusions: Blonanserin transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability.
Introduction
Despite the availability of various dopamine-derived drugs, a consistent issue in the management of schizophrenia is a poor adherence to antipsychotic medication (Alvarez-Jimenez et al., 2012; Weiden et al., 2004) . Factors associated with poor adherence vary among studies, and include lower socio-economic and education status, lack of selfrecognition of the mental disorder, substance abuse, debatable effectiveness, adverse events (AEs), stigma, and cognitive impairment (Kreyenbuhl et al., 2009; Velligan et al., 2017) .
Antipsychotics are currently available only as oral and injectable formulations. Injectable preparations obviate the need for daily pill-taking but are used in only a minority of patients (Correll et al., 2018) . These agents are often seen as a "treatment of last resort", and many patients find injectable therapy stigmatizing or too uncomfortable (Das et al., 2014; Patel et al., 2009) . There is an unmet need for antipsychotic formulations that are acceptable to patients but can also enhance adherence and adherence monitoring. Transdermal formulations may be beneficial for the treatment of schizophrenia, as the patch can be hidden under clothing and may be a better option for patients who are embarrassed to be seen swallowing tablets or attending the clinic for injections. Additionally, a transdermal patch expands the range of treatment options for physicians and patients to consider when engaged in shared decision-making (SDM). Transdermal patches may also have an advantage of easy supervision by the medical staff or caregiver, and of providing observable proof of treatment adherence. With these advantages, a transdermal patch of blonanserin may improve treatment adherence in patients with schizophrenia, with reduced AEs (Sumitomo Dainippon Pharma Co., Ltd., 2018) .
Blonanserin is a second-generation antipsychotic that improves the positive, negative, and cognitive symptoms of schizophrenia by blocking the D 2 , D 3 , and 5-HT 2A receptors (Hori et al., 2014; Kishi et al., 2019; Une and Kurumiya, 2007) . Blonanserin has negligible affinities for 5-HT 2C , adrenergic α1, histamine H 1 , and muscarinic M 1 receptors. Blonanserin is associated with a low risk of weight gain, abnormal lipid or glucose metabolism, and cardiovascular complications (Kishi et al., 2014; Kishi et al., 2019; Miura, 2008; Murasaki, 2007) , as well as a low risk of excessive sedation due to low affinity to H 1 and histaminergic receptors. It is approved to treat schizophrenia in Japan, Korea, and China, and is currently available as tablet or powder formulations (Korea Food and Drug Administration; Osaka Dainippon Sumitomo Pharma Co. Ltd, 2009) . The aim of this study was to determine the efficacy, safety, and pharmacokinetics of the blonanserin transdermal patch in patients with an acute exacerbation of schizophrenia.
Methods

Study design and participants
This was a randomized, double-blind, multicenter, placebocontrolled, phase 3 study (ClinicalTrials.gov identifier: NCT02287584). Patients aged ≥18 years with schizophrenia as per the Diagnostic and Statistical Manual of Mental Disorders, fifth edition diagnostic criteria, an exacerbation of psychiatric symptoms b2 months before screening, a Positive and Negative Symptom Scale (PANSS) score of ≥4 for ≥2 of the following items: delusions, conceptual disorganization, hallucinations, suspiciousness, and unusual thought content, a PANSS total score of ≥80, and who were hospitalized from the time of screening to the scheduled date of Week 2 were enrolled. Key exclusion criteria included: prior blonanserin treatment; receipt of a central nervous system depressant, adrenaline, azole antifungals (excluding external use), or human immunodeficiency virus protease inhibitors; history of neuroleptic malignant syndrome, tardive dyskinesia or water intoxication; suicidal tendency or previous suicide attempts; a hemoglobin A1c ≥8.4%; a history of drug or alcohol abuse/addiction b180 days before screening; receipt of a depot preparation (SR formulation) antipsychotic, clozapine, monoamine oxidase inhibitor, or fluoxetine or electroconvulsive therapy before screening; and patients considered resistant to treatment for psychiatric symptoms by the investigator. Patients with ≥20% reduction in the PANSS total score between screening and randomization were also excluded. Other major exclusion criteria were patients who received any depot preparation (SR formulation) of antipsychotics within b90 days of screening, clozapine within b120 days of screening, a MAO inhibitor or fluoxetine b30 days before screening and electroconvulsive therapy b180 days before screening. For a full list of exclusion criteria, see Supplementary Table S1 .
The study protocol was reviewed and approved by the Institutional Review Board/Independent Ethics Committee at each study site, and the study was conducted according to the ethical principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All patients (or their caregivers) provided written informed consent.
Randomization and masking
The study included an observation period followed by a 6-week double-blind treatment period ( Supplementary Fig. S1 ). During the observation period, patients applied two patches of placebo once daily for ≥3 days. All patients who completed the observation period were randomized using an interactive voice/web-response system (1:1:1) to receive once daily blonanserin 40 mg (1 blonanserin 40 mg patch +1 placebo patch), blonanserin 80 mg (2 blonanserin 40 mg patches), or placebo (2 placebo patches) applied to the back, chest, or abdomen. All patches and packaging were identical in appearance and investigators, patients and caregivers were blinded to the patient's treatment assignment.
Procedures
PANSS and Clinical Global Impressions-Severity of Illness (CGI-S) were scored on Day 1 (baseline) and at 1, 2, 4, and 6 weeks. The use of antipsychotic, antimanic, anticonvulsant, monoamine oxidase inhibitor, antiparkinsonian (excluding upon onset or exacerbation of extrapyramidal symptoms), psychotropic (excluding upon onset of restlessness, excitement, agitation, etc. when lorazepam 3 mg/day could be used), or hypnotic (excluding upon onset/exacerbation of insomnia when patients could receive triazolam, brotizolam or lormetazepam; zopiclone or eszopiclone; zolpidem; or rilmafazone) drugs was prohibited during the study. When concomitant therapies were required during the study to control persistent or emergent aggravated symptoms, the name and class of the drug, route of administration, start and stop dates, and reason for use were recorded. For antipsychotics and antiparkinsonian drugs, data on their use and daily dose in the 7 days before screening were recorded, and all psychotropic drugs and hypnotic drugs were discontinued b12 h before the PANSS, CGI-S and Columbia-Suicide Severity Rating Scale (C-SSRS) assessments.
Outcomes
The primary endpoint was the change from baseline in the PANSS total score after 6 weeks. Other endpoints included: change from baseline to Week 6 in the PANSS subscale scores, PANSS five-factor model (Lindenmayer et al., 1994) , and CGI-S scores, and the percentage of patients with a ≥20% improvement in total PANSS score after 6 weeks.
All treatment-emergent AEs (TEAEs) reported during the doubleblind treatment period were recorded and classified using MedDRA Version 19.1. The safety endpoints included: all TEAEs, extrapyramidal TEAEs, skin-related TEAEs at the application site, assessment of skin irritation reactions at the application site, change in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) (Inada et al., 2003) total score from baseline to Week 6 (excluding overall severity), serum prolactin levels, electrocardiogram (ECG) parameters (QTc), concomitant use of antiparkinsonian drugs, suicidal ideation and behavior (as assessed by the C-SSRS (Posner et al., 2011) scores), and laboratory test values, vital signs, and bodyweight.
DIEPSS (Inada et al., 2003) , C-SSRS (Posner et al., 2011) , skin irritation, bodyweight, and vital signs were evaluated on Day 1 and 1, 2, 4, and 6 weeks; laboratory tests were conducted on Day 1 and 2 and 6 weeks, and 12 lead ECG was performed on Day 1 and 1, 2 and 6 weeks. Skin irritation was assessed on a 6-grade score as negative; faint erythema; erythema; erythema + edema; erythema + edema + papules, serous papules, vesicles; and coalescing vesicles (Kawamura et al., 1970) .
Blood samples of patients were collected under fasting conditions at Week 1, 2, and 6 during the double-blind treatment period and used for the determination of plasma concentrations of blonanserin.
Pharmacokinetics
Plasma blonanserin and the major metabolite (N-deethyl compound) concentrations were measured. Blood sampling was conducted at weeks 1, 2 and 6. The sampling timings in hours after administration were not defined. LC-MS/MS was used to measure the concentrations.
Statistical analysis
A sample size of 167 patients per group was estimated to demonstrate a significant difference in the primary endpoint. The sample size calculations are described in more detail in Supplementary Methods.
The efficacy analysis was conducted in the modified intention-totreat population (mITT), including all patients who applied ≥1 transdermal patches during the study period and who had baseline and ≥ 1 postbaseline total PANSS scores available. Safety was analyzed in the safety analysis set, which included all patients who applied ≥1 patch during the study period. Pharmacokinetics were analyzed in all patients who received treatment with ≥1 blonanserin patch during the study period, and for whom valid data for plasma blonanserin levels were available.
The change from baseline to Week 6 in PANSS, CGI-S and DIEPSS scores were analyzed using the Mixed Model for Repeated Measures (covariates: treatment group, study visit, study site, relevant baseline scores, treatment-by-visit interaction). The analysis of the primary endpoint involved multiplicity adjustment using the Hochberg method tested with a two-sided 5% significance level (p b 0.05); multiplicity adjustment was not used for other analyses, but p b 0.05 was still considered significant in these analyses.
The number and the frequency of TEAEs and patients showing suicidal ideation or suicide attempt at least once in C-SSRS, as well as summary statistics of laboratory test parameters, vital signs, bodyweight, and 12 lead ECG were calculated for each treatment group. Plasma blonanserin levels were determined in each treatment group and the timing for each evaluation was noted.
Results
Patient disposition and baseline characteristics
The study was conducted between December 2014 and October 2018 at 108 medical facilities across Japan, China, Korea, Malaysia, Philippines, Russia, Taiwan, and Ukraine. Of the 675 patients who consented to participate in the study, 580 were randomized and 77.2% completed treatment (72.6%, 76.0%, and 83.0% in the placebo, blonanserin 40 mg, and blonanserin 80 mg groups, respectively; Fig. 1 ). The main reasons for patient withdrawal were: AEs, withdrawal of consent, and lack of efficacy.
There were no major differences in the demographic or clinical characteristics of patients in the three groups at baseline (Table 1) .
The mean duration of patch application in the mITT population was 35.6 ± 12.05 days. During the treatment period, 73.8% of patients received concomitant medications, including antiparkinsonian drugs (3.2%, 6.6%, and 14.1% of patients in the placebo, blonanserin 40 mg, and blonanserin 80 mg groups, respectively), psychotropic agents (43.9%, 43.9%, and 43.8%), and hypnotic agents (38.6%, 35.7%, and 41.1%).
Efficacy
After 6 weeks of treatment, the difference in the least squares mean (LSM) change from baseline in PANSS total score compared with placebo was −5.6 with blonanserin 40 mg (95% confidence interval [CI] −9.6, −1.6; adjusted p = 0.007) and − 10.4 with blonanserin 80 mg (95%CI −14.4, −6.4; adjusted p b 0.001; Fig. 2A ). The proportion of patients with ≥20% reduction from baseline in the PANSS total score at 6 weeks was 42.3% with placebo versus 50.5% with blonanserin 40 mg (odds ratio [OR] 1.49; 95%CI 0.97, 2.30; p = 0.068, number needed-totreat [NNT] = 13) and 55.7% with blonanserin 80 mg (OR 1.92; 95%CI 1.24, 2.97; p = 0.003, NNT = 8).
After 6 weeks, the LSM changes from baseline in PANSS subscale scores were significantly better with blonanserin 80 mg compared with placebo for the positive subscale (−2.9; 95%CI −4.2, −1.6; p b 0.001; Fig. 2B ), negative subscale (−2.7; 95%CI −3.7, −1.6; p b 0.001; Fig. 2C ), and general psychopathology subscale (−4.6; 95%CI −6.6, −2.6; p b 0.001; Fig. 2D ), and significantly better with blonanserin 40 mg compared with placebo for the negative subscale (−1.6; 95%CI −2.7, −0.5; p = 0.004; Fig. 2C ) and general psychopathology subscale (−2.8; 95%CI −4.8, −0.8; p = 0.005; Fig. 2D ).
The scores of each factor of the PANSS five factor model except anxiety/depression decreased significantly from baseline at Week 6 with blonanserin 80 mg versus placebo (treatment difference for negative symptoms: −2.2, 95%CI −3.2, −1.2, p b 0.001; excitement: −1.4, 95% CI −2.1, −0.7, p b 0.001; cognitive disorders: −1.9, 95%CI −2.6, −1.2, p b 0.001; positive symptoms: −1.5, 95%CI −2.3, −0.7, p b 0.001; anxiety/depression: −0.6, 95%CI, −1.3, 0.0, p = 0.056; Supplementary  Fig. S2 ). Blonanserin 40 mg showed significant improvements compared with placebo for negative symptoms (treatment difference −1.5; 95%CI −2.5, −0.5; p = 0.004) and cognitive disorders (−1.1; 95%CI −1.8, −0.4; p = 0.002).
The CGI-S score decreased from baseline to Week 6 with blonanserin 40 mg and 80 mg; this improvement was significant versus placebo with blonanserin 80 mg (treatment difference − 0.40; 95%CI −0.62, −0.18; p b 0.001; Supplementary Fig. S3 ), but not with blonanserin 40 mg (−0.16; 95%CI −0.38, 0.06; p = 0.149).
Safety
TEAEs were reported in similar proportions of patients receiving placebo, blonanserin 40 mg, and 80 mg (Table 2) . TEAEs rated as severe were akathisia (80 mg, 0.5%), schizophrenia (placebo, 2.6%; 40 mg, 2.0%; 80 mg, 1.5%), and psychotic disorder (placebo, 0.5%; 40 mg, 1.0%). The incidence of serious TEAEs reported during the study was similar among the three groups and TEAEs requiring treatment discontinuation were reported in 17 (8.9%), 16 (8.2%), and 11 (5.7%) patients receiving placebo, blonanserin 40 mg, and 80 mg, respectively. None of the TEAEs that caused treatment discontinuations were specifically related to the application site. One patient in the blonanserin 80 mg group died from an acute myocardial infarction, which was not considered treatment related.
Serious TEAEs in which a causal relationship to blonanserin could not be ruled out included: schizophrenia (n = 2), generalized tonicclonic seizure (n = 1), psychiatric disorder (n = 1), and psychiatric symptom (n = 1) with blonanserin 40 mg; schizophrenia (n = 2) and suicide attempt (n = 1) with blonanserin 80 mg; and catatonia (n = 1) and loss of consciousness (n = 1) with placebo.
Extrapyramidal TEAEs were reported in 7.9%, 10.7%, and 20.6% of patients in the placebo, blonanserin 40 mg, and 80 mg groups, respectively (Table 2) , most of which were considered mild/moderate (one case of akathisia in the blonanserin groups and one case of psychomotor hyperactivity in the placebo group were considered as severe). Extrapyramidal TEAEs reported in ≥2% of patients included tremor (2.6%) and restlessness (2.1%) in the placebo group, akathisia (5.6%) and tremor (4.1%) in the blonanserin 40 mg group, and gait disturbance (2.1%), muscle rigidity (3.6%), akathisia (9.8%), tremor (8.8%), bradykinesia (3.1%), and dyskinesia (2.6%) in the blonanserin 80 mg group.
Skin-related TEAEs at the site of patch application were reported in 4.2%, 13.3%, and 18.6% of patients in the placebo, blonanserin 40 mg, and 80 mg groups, respectively, none of which were considered severe. Most skin-related TEAEs in the blonanserin treatment groups occurred within 2 weeks of starting treatment (Supplementary Table S2 ). Skinrelated TEAEs reported in ≥2% of patients included application site erythema (5.6%), pruritus (5.1%), and dermatitis (2.0%) in the blonanserin 40 mg group, and application site erythema (9.3%) and pruritus (7.2%) in the blonanserin 80 mg group. Topical steroids and topical antihistamines were used by 2.9% and 0.3% of patients in the whole cohort.
Among the patients who showed skin-related TEAEs (n = 70), approximately half (n = 36) received any treatment, including topical steroids (n = 17), topical antihistamines (n = 2) and others (n = 17, e.g., moisturizer). Most patients with skin-related TEAEs recovered from these by the end of the study. Twenty-four patients were not recovered by the end of the study and nine among them were still on treatment with topical steroids at the end of the study period. All of these nine patients had skin-related TEAEs considered as mild.
Overall, 5.9%, 7.7%, and 8.3% of patients in the placebo, blonanserin 40 mg, and 80 mg groups, respectively, gained ≥7% bodyweight from baseline, and 2.7%, 5.6%, and 4.1%, respectively lost ≥7% bodyweight from baseline. Mean change in the bodyweight from baseline at Week 6 was −0.30 ± 2.44 kg, 0.10 ± 2.76 kg, and 0.22 ± 2.47 kg with placebo, blonanserin 40 mg, and 80 mg, respectively. The incidence of metabolism-related TEAEs, abnormal laboratory findings (Supplementary Table S3 ) and abnormal ECG findings (Table 2) were also similar between the three groups at the end of the treatment period. The LSM difference in change in DIEPSS total score from baseline to Week 6 compared with placebo was 0.2 (95%CI −0.1, 0.5; p = 0.259) with blonanserin 40 mg and 0.3 (95%CI 0.0, 0.6; p = 0.032) with blonanserin 80 mg. The C-SSRS evaluation showed suicidal ideation after baseline in 2.6%, 5.6%, and 3.1% of patients in the placebo, blonanserin 40 mg, and blonanserin 80 mg groups; the maximum score of suicidal ideation worsened from baseline in 1.1% of patients in the placebo group versus 3.1% and 1.6% in the blonanserin 40 mg and 80 mg groups.
In skin irritation assessment, a negative score was most frequent in the three groups (82.5% vs 77.6% and 70.5% with placebo, blonanserin 40 mg and 80 mg), followed by faint erythema (12.2% vs 11.7% and 13.0%), and erythema (4.2% vs 8.7% and 14.5%). No patient developed coalescing vesicles during the double-blind treatment period.
Pharmacokinetics
Mean plasma blonanserin concentrations increased with treatment during the double-blind treatment period (Table 3 ). The mean plasma blonanserin concentration with blonanserin 80 mg was approximately twice that of blonanserin 40 mg at each evaluation time point.
Discussion
This randomized, double-blind, placebo-controlled, phase 3 trial was the first study to investigate the efficacy and safety of the blonanserin transdermal patch in patients with acute schizophrenia. After 6 weeks of treatment the blonanserin transdermal patch improved the symptoms of schizophrenia, as reflected by reduced PANSS total and subscale scores and CGI-S scores. Treatment with transdermal blonanserin patch was well tolerated, with manageable TEAEs.
The change from baseline in PANSS total score with the 80 mg blonanserin patch at 6 weeks in this study was higher in magnitude than that at Week 8 of treatment with blonanserin tablets in the phase 3 studies conducted in Japanese patients (mean decrease of 10 to 11 points) (Kishi et al., 2019; Korea Food and Drug Administration, 2016) . In contrast, the placebo-corrected change in PANSS total score with the 80 mg blonanserin patch at 6 weeks in this study was somewhat lower than that seen with blonanserin tablets in a randomized, placebo-controlled study in non-Japanese patients (Sumitomo Dainippon Pharma Co., Ltd., 2018). However, the effect size with the blonanserin 80 mg patch (0.555) is considered a "medium" effect size (Leppink et al., 2016) , which suggests that blonanserin may not be inferior to other drugs available for the treatment of schizophrenia. It should be noted, however, that in this fixed dose study, neither responder rate nor CGI-S showed a significant difference with blonanserin 40 mg vs placebo. It is suggested to observe effectiveness carefully and to consider a clinically appropriate dose increase when insufficient effectiveness is observed on the blonanserin 40 mg patch.
The blonanserin 80 mg group also showed significantly greater reductions in the positive, negative, and general psychopathology PANSS subscale scores at 6 weeks compared with placebo, and improvements in all factors except anxiety/depression of the PANSS five-factor model. Antipsychotics have been shown to be less effective in treating the negative than the positive symptoms of schizophrenia (Krause et al., 2018; Leucht et al., 2017) . Some negative symptoms, such as anhedonia and avolition, appear to be mediated by dopamine D 3 receptors (Duric et al., 2017; Simpson et al., 2014) . Conversely, a PET study in patients with schizophrenia was unable to demonstrate a relationship between the extent of dopaminergic D 2/3 occupancy by antipsychotics and the magnitude of effect on negative symptoms (Fervaha et al., 2016) . A clinical dose of blonanserin occupied D 3 receptors as much as D 2 receptors, which was demonstrated by a PET study in human (Tateno et al., 2018) . Therefore, the effect on negative symptoms with blonanserin may reflect potent inhibition for the D 3 receptor in vivo. Further research using a longer duration of treatment in patients with .3) Mean ± SD no. of schizophrenia episodes 3.7 ± 1.4 3.7 ± 1.3 3.8 ± 1.4 3.7 ± 1.4 Mean ± SD age at the first onset of schizophrenia, years 27.6 ± 10.1 26.8 ± 9.5 26.5 ± 9.6 27.0 ± 9.7 Mean ± SD duration of illness a , years 13.9 ± 11.9 13.8 ± 11.2 13.8 ± 12.2 13.8 ± 11.7 Mean ± SD duration of current episode b , months 2.9 ± 22.0 3.7 ± 25.9 3.8 ± 32.1 3.5 ± 27.0 Mean ± SD PANSS total score 99. Values are presented as n (%) unless otherwise stated. BMI, body mass index; CGI-S, clinical global impressions-severity of illness scale; DIEPSS, drug-induced extrapyramidal symptoms scale; No. number; PANSS, positive and negative syndrome scale; SD, standard deviation. a Duration of illness indicates years from the initial episode of schizophrenia to the informed consent. b Duration of current episode is months from the onset of current episode to the informed consent. c Score excluding overall severity.
predominantly negative symptomatology is required to clarify the effects of blonanserin on negative symptoms. Of the TEAEs reported by ≥5% of patients during this study, the incidence of schizophrenia was mainly higher in the placebo group, while application site erythema and pruritus, akathisia, and tremor were more common in the blonanserin treatment groups. In common with other dopamine receptor drugs antagonists/partial agonists (Divac et al., 2014) and with blonanserin tablets (Kishi et al., 2019) , akathisia and tremor were the most frequently observed extrapyramidal TEAEs in the two treatment groups; however, none of these events were considered serious. In addition, the incidence of akathisia with blonanserin 80 mg was lower than that reported in previous clinical studies of blonanserin tablets (15.6-35.5%) (Garcia et al., 2009; Li et al., 2015; Murasaki, 2007) . The overall incidence of extrapyramidal TEAEs reported with blonanserin 80 mg in the present study was also lower than that reported in previous clinical studies of blonanserin tablets (26.6-66.7%) (Garcia et al., 2009; Li et al., 2015; Murasaki, 2007) . In addition, in contrast to the incidence of overall AEs with blonanserin tablets reported in other studies, which were comparable to the respective control groups (93% vs 96% [haloperidol] and 98% vs 99% [risperidone]), AEs with blonanserin patch in our study occurred in only 63% (40 mg) and 67% (80 mg) (Harvey et al., 2019; Miura, 2008) . Although it may not be appropriate to make a direct comparison of these values due to the differences in study designs and baseline characteristics of enrolled patients, this lower incidence of overall AEs or extrapyramidal TEAEs could possibly be due to more stable plasma blonanserin levels observed with the transdermal patch compared with its oral formulations. A dose-dependent increase in the plasma concentrations of blonanserin during the double-blind treatment period was seen in this study. In terms of efficacy, PANSS total score, as well as subscale scores showed positive dose associations. In terms of safety, most events increased with blonanserin 80 mg vs 40 mg treatment, with some exceptions such as insomnia, sedation and psychiatric disorders. Plasma level stability with the patch formulation may be related to the direct absorption of blonanserin from the skin, which bypasses the gastrointestinal tract and therefore the typical effect of food on the bioavailability of oral blonanserin is not seen (Saruwatari et al., 2010) . Furthermore, the blonanserin patch provides continuous release of blonanserin, which may also contribute to this stability (Sumitomo Dainippon Pharma Co., Ltd., 2018) .
The incidence of skin-related TEAEs (application site erythema, pruritus, and dermatitis) increased dose-dependently with blonanserin during the study; however, none of these were considered serious and were managed with topical steroids or antihistamines. Moreover, no premature treatment discontinuation was reported due to these TEAEs.
Blonanserin may be associated with a low risk of weight gain and hyperprolactinemia (Kishi et al., 2014) . The proportion of patients with a ≥ 7% weight gain in the current study was low in all three treatment groups. These safety findings also need to be confirmed in another long-term study of the blonanserin patch.
The treatment completion rate in the present study was 76% with the blonanserin 40 mg patch and 83% with blonanserin 80 mg, which compares favorably with the 73.3% treatment completion rate seen with blonanserin tablets in a randomized, multicenter trial of blonanserin versus risperidone in the management of Chinese patients with schizophrenia (Li et al., 2015) . Our finding suggests that the blonanserin patch may improve treatment persistence in patients with schizophrenia, although this possibility needs to be confirmed in additional studies of longer duration and with a direct pill comparator.
Patients with schizophrenia require long-term treatment (Correll et al., 2018) , but adherence to treatment is often poor, which increases the risk of re-hospitalization (Weiden et al., 2004) . We hypothesized that using the transdermal route for drug administration would not only enhance adherence (relative to oral antipsychotics) but would allow treatment adherence to be easily monitored by the treating physicians and caregivers. Importantly, transdermal patches also offer an alternative to both oral and intramuscular antipsychotic agents, thereby expanding the options for consideration during treatment decisions. Having a range of treatment options is especially important in SDM models of psychiatric care, which are being increasingly adopted into mental health policy around the world. The transdermal option may be particularly useful for patients with a long duration of schizophrenia who may have developed preferences for and against particular antipsychotic agents during the course of their treatment.
The main limitation of the present study was that multiplicity adjustment was not used in the statistical analysis, except for analysis of the primary endpoint. Another limitation of the study is the relatively short study duration of 6 weeks, although results from the ongoing open-label extension of this study are expected to provide data on the long-term safety and efficacy (up to 52 weeks) of blonanserin transdermal patch in the treatment of schizophrenia. Also, the study only enrolled patients aged over 18 years and the results may not be fully generalizable to younger patient populations. Finally, the comparator was placebo and future studies should include a tablet version of blonanserin or another antipsychotic.
In conclusion, transdermal blonanserin patch showed efficacy in the treatment of acute stage schizophrenia, as indicated by effective management of the positive and negative symptoms of schizophrenia during the study period. Blonanserin was also well tolerated and showed a dose-dependent improvement in both psychopathology and treatment completion rates over placebo. These findings suggest that the once-daily transdermal patch formulation of blonanserin provides an effective and well-tolerated treatment option for patients with acute schizophrenia, and expands the options for patients to consider during schizophrenia management. We also found from this study that the incidence of some skin-related AEs increased in a dose-dependent manner. This phenomenon needs to be assessed further in future studies. The outcomes of this study are being further tested in a long-term follow-up in Japan, although another study with a comparator arm is needed to confirm its long-term efficacy on the negative and positive symptoms of schizophrenia.
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